ECSP044981A - Composicion oftalmica que comprende ascomicina - Google Patents

Composicion oftalmica que comprende ascomicina

Info

Publication number
ECSP044981A
ECSP044981A EC2004004981A ECSP044981A ECSP044981A EC SP044981 A ECSP044981 A EC SP044981A EC 2004004981 A EC2004004981 A EC 2004004981A EC SP044981 A ECSP044981 A EC SP044981A EC SP044981 A ECSP044981 A EC SP044981A
Authority
EC
Ecuador
Prior art keywords
ascomycin
ophthalmic composition
ophthalmic
day
relates
Prior art date
Application number
EC2004004981A
Other languages
English (en)
Inventor
Jean Claude Bizec
Christian Schoch
Michelle Pik Han Wong
Maggy Babiole Saunier
Andrea Fetz
Kasey Jon Minick
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23219986&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP044981(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP044981A publication Critical patent/ECSP044981A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Esta invención se refiere a composiciones oftálmicas que comprenden una ascomicina, para administrarse una vez al día.
EC2004004981A 2001-08-23 2004-02-18 Composicion oftalmica que comprende ascomicina ECSP044981A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31444801P 2001-08-23 2001-08-23

Publications (1)

Publication Number Publication Date
ECSP044981A true ECSP044981A (es) 2004-04-28

Family

ID=23219986

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004004981A ECSP044981A (es) 2001-08-23 2004-02-18 Composicion oftalmica que comprende ascomicina

Country Status (27)

Country Link
US (2) US20030050255A1 (es)
EP (1) EP1420787B8 (es)
JP (1) JP2005501105A (es)
KR (2) KR20100089108A (es)
CN (1) CN100366251C (es)
AR (1) AR035293A1 (es)
AT (1) ATE452638T1 (es)
AU (1) AU2002331172B2 (es)
BR (1) BR0211972A (es)
CA (1) CA2457034C (es)
CO (1) CO5560568A2 (es)
DE (1) DE60234840D1 (es)
EC (1) ECSP044981A (es)
ES (1) ES2337130T3 (es)
HU (1) HUP0402396A3 (es)
IL (1) IL160374A0 (es)
MX (1) MXPA04001646A (es)
MY (1) MY157377A (es)
NO (1) NO20040775L (es)
NZ (1) NZ531224A (es)
PE (1) PE20030311A1 (es)
PL (1) PL208685B1 (es)
PT (1) PT1420787E (es)
RU (1) RU2313344C2 (es)
TW (1) TWI324925B (es)
WO (1) WO2003017990A2 (es)
ZA (1) ZA200400772B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
BE1015610A3 (nl) * 2003-07-17 2005-06-07 Corrutech Nv Verbeterde lijm en werkwijze voor het vervaardigen ervan.
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
WO2009007839A1 (en) * 2007-07-11 2009-01-15 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
MY161021A (en) 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2010011605A2 (en) 2008-07-21 2010-01-28 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
CA2751761A1 (en) 2008-10-22 2010-04-29 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
CN105682742A (zh) 2013-08-27 2016-06-15 奥德纳米有限公司 小儿耳部病症的治疗
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. OTIC GEL FORMULATIONS FOR THE TREATMENT OF EXTERNAL OTITIS
JP7699426B2 (ja) * 2018-11-30 2025-06-27 ロート製薬株式会社 光線による障害からの細胞保護用眼科組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE132366T1 (de) * 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
DK0786986T3 (da) * 1994-10-26 2002-04-29 Novartis Ag Anvendelse af en umættet fedtalkohol
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
JP4221762B2 (ja) * 1997-04-11 2009-02-12 アステラス製薬株式会社 医薬組成物
CZ287497B6 (cs) * 1997-12-30 2000-12-13 Galena, A. S. Topické oční přípravky s imunosupresivními látkami
CZ20013769A3 (cs) * 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka

Also Published As

Publication number Publication date
CO5560568A2 (es) 2005-09-30
WO2003017990A3 (en) 2003-08-28
JP2005501105A (ja) 2005-01-13
IL160374A0 (en) 2004-07-25
PE20030311A1 (es) 2003-05-08
WO2003017990A2 (en) 2003-03-06
EP1420787B1 (en) 2009-12-23
KR20040030157A (ko) 2004-04-08
DE60234840D1 (de) 2010-02-04
PT1420787E (pt) 2010-03-01
RU2004108463A (ru) 2005-05-10
ATE452638T1 (de) 2010-01-15
AU2002331172B2 (en) 2005-12-01
MXPA04001646A (es) 2004-05-31
HUP0402396A2 (hu) 2005-09-28
RU2313344C2 (ru) 2007-12-27
EP1420787A2 (en) 2004-05-26
PL208685B1 (pl) 2011-05-31
CA2457034A1 (en) 2003-03-06
KR20100089108A (ko) 2010-08-11
HUP0402396A3 (en) 2005-12-28
ES2337130T3 (es) 2010-04-21
HK1065961A1 (en) 2005-03-11
EP1420787B8 (en) 2010-09-01
CA2457034C (en) 2010-07-27
US20110071186A1 (en) 2011-03-24
BR0211972A (pt) 2004-09-21
CN100366251C (zh) 2008-02-06
PL367459A1 (en) 2005-02-21
MY157377A (en) 2016-06-15
NZ531224A (en) 2005-09-30
CN1545414A (zh) 2004-11-10
US20030050255A1 (en) 2003-03-13
TWI324925B (en) 2010-05-21
ZA200400772B (en) 2004-10-11
NO20040775L (no) 2004-02-17
AR035293A1 (es) 2004-05-05

Similar Documents

Publication Publication Date Title
AR035293A1 (es) Composicion oftalmica.
CR8767A (es) Indazoles sustituidos, composiciones que los contienen, procedimiento de preparacion y su uso
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
NO20082191L (no) Forbindelser
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
MY135233A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
LTC1608344I2 (lt) Per burną vartojamos kladribino kompozicijos
PA8625201A1 (es) Composiciones de peróxido estabilizadas
MX2007006558A (es) Formulaciones topicas de nepafenac.
BRPI0411472A (pt) composição adesiva de cianoacrilato, método de preparação da mesma, e método de aglutinação de dois substratos entre si
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
ATE330017T1 (de) Kallikrein gen
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
PA8571901A1 (es) Nueva composicion farmaceutica
ATE397861T1 (de) Synergistische zusammensetzungen
FI20030779A0 (fi) Matriisinauha
BRPI0417205A (pt) composições farmacêuticas
BRPI0313645A2 (pt) composições de inalação com relações de droga elevadas.
PL1843778T3 (pl) Kompozycje zawierające galusan epigalokatechiny i hydrolizat białkowy
WO2006052880A8 (en) Synergistic effects of combined administration of mirtazapine and a stimulant compound
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
WO2005094761A8 (en) Hair treatment compositions comprising a disaccharide, a di-acid and a source of ammonium ions